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Globally, high blood pressure (BP) is the leading single risk factor for 
cardiovascular disease, and the prevalence continues to escalate.[1,2] 
Hypertension is an independent risk factor for peripheral vascular 
disease, heart failure, coronary artery disease, stroke and end-
stage renal disease.[3] According to National Health and Nutrition 
Examination Survey data, the prevalence of resistant hypertension 
is 12.8% of treated subjects in the USA.[4] A patient’s usual BP is 
‘strongly and directly’ associated with cardiovascular and overall 
mortality, and lowering the BP reduces this risk.[5] Despite the 
unquestionable benefits of treating hypertension, consistent control of 
BP is an elusive goal. Although control of BP varies widely in different 
countries, a consistent finding is that ~50% of treated patients fail 
to achieve a goal of <140/90 mmHg.[6] Long-term adherence is 
a key factor associated with BP control,[7] and lack of adherence 
is associated with increased all-cause mortality in hypertensive 
patients. [8] In a longitudinal study of antihypertensive dosing histories 
of 4 783 patients in 21 phase IV clinical studies where patients were 
prescribed once-a-day antihypertensive treatment, about half of the 
patients had stopped taking their treatment within 1 year, and in 
many there was poor execution of treatment.[9] Furthermore, in a 
cross-sectional analysis of 2 180 patients in Louisiana, USA, ~50% 
had low to medium adherence to antihypertensives, associated with 
an increased risk of uncontrolled hypertension.[10] Reasons cited for 
non-adherence were lack of access to medication, inadequate patient 
self-issuing of medication and poor patient-doctor interaction.
Monitoring antihypertensive therapy adherence is essential to 
define whether patients are truly treatment resistant and to avoid 
unnecessary special investigations and medication costs in response 
to poor BP control. Adherence assessment is challenging. Methods 
that have been used are self-reported adherence, pill counting, 
telephonic questioning, monitoring electronic pharmacy refill 
records and pharmacist monitoring. Each of these methods is limited 
by the fact that they do not measure whether the patient actually 
ingested the medication.
Therapeutic drug monitoring (TDM) is frequently employed 
in chronic diseases such as epilepsy and HIV to optimise medi-
cation dosing. During TDM a steady-state medication plasma 
concentration, at a particular time point, is measured and compared 
with a known therapeutic range. This range consists of an upper toxic 
concentration and a lower sub-therapeutic concentration. Following 
TDM, medication dosing may be adjusted to optimise efficacy and 
minimise toxicity. In practice, TDM is frequently used as a measure 
of adherence.[11] TDM of antiepileptic medications has revealed that 
low plasma concentrations predict the risk of status epilepticus. [12] 
Assays have been developed to determine adherence in clinical 
trials,[13] but this has not been applied in clinical practice.
The usefulness of TDM as an adherence measure is limited by 
inferences about long-term adherence. Medications with a short 
half-life do not reach steady state, and plasma concentrations only 
reflect adherence to the last dose taken. TDM monitoring is most 
useful in medications where there is a correlation between plasma 
concentrations and clinical effect or toxicity and those with a narrow 
therapeutic index. Amlodipine, a calcium channel blocker used as a 
first-line antihypertensive agent, has a long elimination half-life of 
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Objective. To determine whether monitoring plasma amlodipine concentrations and inhibition of angiotensin-converting enzyme (ACE) 
can be adjunct adherence tools.
Methods. Patients with hypertension who were prescribed enalapril and amlodipine were enrolled. Blood pressures (BPs) were monitored 
and an adherence questionnaire was completed. Steady-state amlodipine was assayed using liquid chromatography-mass spectrometry and 
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~60 hours.[14] Furthermore, amlodipine steady-state trough plasma 
concentrations at different doses have been established (Table 1) and 
are related to clinically relevant BP lowering. These factors make 
amlodipine ideal for TDM to measure adherence.
The Z-FHL/HHL (z-phenylalanine-histidine-leucine/hippuryl-
histidine-leucine) ratio is a measure of the inhibition of serum 
angiotensin-converting enzyme (ACE) by ACE inhibitors such as 
enalapril, the commonly used ACE inhibitor in South Africa. Lack of 
inhibition of serum ACE as determined by the Z-FHL/HHL ratio is 
considered a measure of the lack of ACE inhibition.[18]
According to the 2014 South African Hypertension Guideline, 
calcium channel blockers, including amlodipine, and ACE inhibitors, 
such as enalapril, are the cornerstones of antihypertensive therapy in 
conjunction with thiazide diuretics.[19]
Objective
To determine whether a random steady-state plasma amlodipine 
concentration and Z-FHL/HHL ratio in the clinic setting could 
independently indicate adherence to medication for BP control. 
Owing to the long half-life of amlodipine, it is unlikely that 
occasional missed doses would be detected with amlodipine plasma 
concentrations. However, it is likely that this method would detect 
clinically relevant chronic non-adherence to amlodipine. The Z-FHL/
HHL ratio would assist in detecting missed doses of enalapril.
Trough amlodipine plasma concentrations were used in 
conjunction with the Z-FHL/HHL ratio to help determine both 
short- and long-term patient non-adherence.
Methods
Patients attending a referral hypertension clinic for apparent 
treatment-resistant hypertension, who were receiving both enalapril 
and amlodipine with additional antihypertensives, were enrolled 
into the study. After providing written informed consent, patients 
underwent BP monitoring and completed a questionnaire relating 
to administration of medication, use of pill boxes, dosing schedule, 
names of the medications, dosage and omission of medication. Trough 
blood samples were taken for amlodipine plasma concentrations and 
the Z-FHL/HHL ratio as a measure of inhibition of ACE. The same 
assessments were repeated at the next follow-up visit.
The University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee approved the study (ref. no. 169/2013).
BP measurement and adherence questionnaire
BP was measured in the seated position at 2-minute intervals 
after 5 minutes’ rest, using an ambulatory BP monitor (Spacelabs 
Healthcare, USA) with an appropriate-sized cuff. The means of six 
BPs were used to assess BP control. Patients were questioned about 
their knowledge of the dose, timing and names of their medications. 
They were asked who issued the medications, whether a pill box was 
used, and to indicate how adherent they were with the medications.
Amlodipine assay
Plasma amlodipine concentrations were determined using a validated 
liquid chromatography-tandem mass spectrometry assay developed 
in the Division of Clinical Pharmacology, University of Cape Town. 
The assay was validated over the concentration range 0.117 - 30 ng/
mL. A concentration of <2.5 ng/mL for amlodipine was considered 
undetectable and >7 ng/mL was considered steady state. Values 
between 2.5 and 7 ng/mL were indeterminate.[14]
The trough blood samples were processed with a protein 
precipitation extraction method using 100 µL plasma with 200 µL 
precipitation solution (acetonitrile) containing a stable isotope-
labelled internal standard, amlodipine-d4, at a concentration of 
1 ng/mL.
Isocratic chromatographic separation was achieved on a Luna C18 
5 µm PFP(2) 5 × 2.0 mm analytical column (Phenomenex, USA). The 
mobile phase consisted of 10 mM ammonium formate and acetonitrile 
(20:80, v/v) and was delivered at a flow rate of 400 µL/min.
An AB Sciex API 5500 Q Trap mass spectrometer (Sciex, USA) was 
operated at unit resolution in the multiple reaction monitoring mode, 
monitoring the transition of the protonated molecular ion m/z 409.0 
to the product ions at m/z 238.0 for amlodipine, and monitoring 
the protonated molecular ions at m/z 413.1 to the product ions at 
m/z 298.0 for amlodipine-d4.
The combined accuracy and precision (expressed as the percent 
coefficient of variation) statistics of the quality controls during inter-
batch validation (N=18; high, medium and low) were 110.2%, 112.2% 
and 110.3% and 4.2%, 3.6% and 4.2%, respectively.
Z-FHL/HHL ratio
ACE activity was measured by the hydrolysis of two synthetic 
substrates (Z-FHL and HHL) in a sensitive fluorimetric assay, as 
described previously.[20] The ratio of enzyme activities obtained with 
substrates Z-FHL and HHL provides a measure of ACE inhibitor 
present in plasma and can be used to detect the presence of any ACE 
inhibitor[18]
Heparinised plasma (10 mL) diluted 1/5 in phosphate-buffered 
saline was incubated with 30 mL of substrate (2 mM for Z-FHL and 
5.7 mM for HHL) in 0.1M potassium phosphate, 0.3M NaCl and 
10 mM ZnSO4, pH 8.3, at 37oC for 1 hour or 5 hours. Plasma samples 
with ACE activity >15 mU/mL using HHL were incubated for 
1 hour. A Z-FHL/HHL ratio of <1.75 was considered to indicate non-
adherence to ACE inhibitors. Reagents were purchased from Merck 
and Sigma-Aldrich (Germany), and benzyloxycarbonyl L-Phe-L-His-
Leu (Z-FHL) from Bachem AG (Switzerland).
Statistical analysis
Descriptive summaries were calculated at baseline using frequency 
(percentages) or medians with interquartile ranges (IQRs). ACE- and 
amlodipine-related values were summarised with means (standard 
deviations (SDs)). Thresholds for suppression v. non-suppression 
(ACE) and for steady state v. undetectable v. indeterminate (amlo-
dipine) were based on available literature and inspection of ACE 
and amlodipine values. Fisher’s exact test was used to compare 
proportions of patients who had controlled v. uncontrolled BPs 
between groups, and the Wilcoxon rank-sum test was used to 
compare BP distributions between classifications.
Results
One hundred patients (mean (SD) age 50.5 (12) years, 46% 
male) were enrolled in the study. Fifty-four percent of patients 
were female, 20% were black African and 80% were of mixed 
ancestry. There were no significant differences in demographic 
characteristics of the patients who had therapeutic concentrations 
of the antihypertensive v. those who did not. Patients were taking 
a median of four antihypertensive medications. All patients were 
taking both an ACE inhibitor and amlodipine. Eighty percent were 
prescribed 10 mg amlodipine daily, and 88% enalapril 10 mg twice 
daily. The majority (90%) of the patients administered their own 
medications, and 24% used pill boxes to assist with adherence. 
Ninety percent of patients knew the dosing schedule, 52% knew 
the names of the medications, 40% knew the dose, and 33% 
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admitted to forgetting to take their medication regularly. There 
was no association between the answers to the questionnaire and 
amlodipine concentrations or ACE activity. All the patients were 
otherwise healthy with no clinical indication of malabsorption, 
and none was taking a medication known to decrease plasma 
concentrations of ACE inhibitors or amlodipine.
ACE inhibitor results
The median Z-FHL/HHL ratio for the entire cohort was 2.61 
(IQR  1.47 - 3.12). Setting a ratio of <1.75 to indicate non-supp-
ression of ACE, 26/97 (26.8%) were not suppressed (Table 2). 
Three patients had missing data. There were significant differences 
in BP when suppression groups were compared based on 
medication concen tration (Table 2). The median BPs were 142 
(IQR  122 - 156)/82 (IQR  72 - 93) mmHg in the suppressed group 
and 163 (IQR  143 - 171)/102 (IQR  89 - 114) mmHg in the non-
suppressed group; all p-values were statistically significant (Table 2). 
Only six patients who had suppressed ACE had BPs >160/100 mmHg 
(Fig. 1).
Amlodipine results
The median amlodipine concentration for the entire cohort was 
13.6 (IQR 5.1 - 4.4) ng/mL. Amlodipine concentrations <2.5 ng/
mL were deemed to be undetectable and were measured in 20/100 
patients (20%). Table 2 shows the BPs based on the patients’ 
plasma concentrations. The dose of amlodipine did not affect serum 
concentrations, although only 14 patients were taking 5 mg daily. 
The mean (SD) amlodipine concentration for the patients on 10 mg 
was 15.6 (12.4) ng/mL and for those on 5 mg 14.9 (19.4) ng/mL. 
Four patients were taking 15 mg amlodipine (concentration range 
0 - 34 ng/mL) and two patients 20 mg (24.2 ng/mL and 25.5 ng/mL). 
The median BPs were 140 (IQR 122 - 149)/84 (IQR 73 - 91) mmHg 
in those with concentrations >7 ng/mL and 166 (IQR 160 - 187)/104 
(IQR  96 - 117) mmHg in those with concentrations <2.5  ng/mL 
(p<0.001 for differences between BPs in the two groups) (Table 2). 
Patients with in-between concentrations had BPs that were 
uncontrolled and between those of the other two groups (Table 2). 
Only two patients with BPs >160/100  mmHg had amlodipine 
concentrations >7 ng/mL (Fig. 1).
Discussion
The major finding of this study was that 20% of patients had an 
undetectable amlodipine concentration and 27% had unsuppressed 
ACE, and this was associated with significantly higher BPs compared 
with those with steady-state concentrations or suppressed ACE.
In addition, the patient questionnaires relating to administration 
of medication, use of pill boxes, knowing the dosing schedule, names 
and dosages of medications and admitting to missing medication did 
not correlate with therapeutic monitoring. We infer that the current 
method of assessing adherence via questioning at clinic visits may 
be inadequate and that the use of TDM may be a helpful adjunct.
Our findings suggest a paradigm shift for evaluating patients with 
apparent treatment resistance, and TDM should become an essential 
additional tool in evaluating these patients. It will not only identify 
patients with true resistance but also reduce the need for expensive 
tests looking for secondary causes, and reduce pill burden, the costs 
of medications and adverse events associated with polypharmacy. 
Furthermore, instead of focusing on over-investigating patients 
with perceived resistant hypertension, determining medication 
concentrations will focus attention on barriers to good adherence 
(e.g. fixed drug combinations or side-effects), preventing further 
costly investigations.[21]
Two recently published studies utilised TDM to determine 
antihypertensive medication adherence.[22,23] However, both these 
studies determined TDM of multiple antihypertensives and used 
24-hour ambulatory BP monitoring, which are not practical options 
in a resource-limited setting such as ours. Our study focused on 
the two most commonly prescribed antihypertensive medications 
Table 1. Steady-state trough concentrations of amlodipine 
Amlodipine dose
Steady state (ng/mL),  
mean (SD) Population
15 mg Cmin 11.8 (5.3) White population, mean (SD) 25.8 (3.8) years[15]
10 mg Cmin 15 (4) Asian population, mean (SD) 42.8 (10.7) years[16]
5 mg Cmin 8.8 (1) White population, range 66 - 77 years[17]
Cmin 7 (1) White population, range 22 - 50 years[17]
SD = standard deviation; Cmin = minimum concentration.
Table 2. Proportion of individuals considered suppressed/non-suppressed (ACE) or in steady state/undetectable (amlodipine) and 
BP, by group
n (%) SBP (mmHg), median (IQR) DBP (mmHg), median (IQR)
Entire cohort (N=100)   146 (127 - 163) 88 (74 - 99)
ACE inhibitor results (N=97)
Suppressed (Z-FHL/HHL ratio >1.76) 71 (73.2) 142 (122 - 156) 82 (72 - 93)
Non-suppressed (Z-FHL/HHL ratio <1.75) 26 (26.8) 163 (143 - 171) 102 (89 - 114)
p-value*   0.0004 <0.0001
Amlodipine results (N=100)
Steady state (>7 ng/mL) 62 (62.0) 140 (122 - 149) 84 (73 - 91)
Undetectable (<2.5 ng/mL) 20 (20.0) 166 (160 - 187) 104 (96 - 117)
Indeterminate (2.5 - 7 ng/mL) 18 (18.0) 159 (138 - 161) 93 (72 - 106)
p-value†   <0.0001 <0.0001
ACE = angiotensin-converting enzyme; BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; IQR = interquartile range.
*Wilcoxon rank-sum test for BP difference between suppressed and non-suppressed.
†Kruskal-Wallis rank-sum test for differences between BP based on medication concentration.
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and suggests that the use of amlodipine 
TDM alone would help to detect complete 
lack of adherence and partial adherence in 
the majority of patients. The likely lack of 
adherence detected by amlodipine TDM in 
our follow-up patients was similar (32% for 
completely and incompletely non-adherent) 
to the 37.9% reported.[23] Quantified plasma 
concentrations of amlodipine allow moni-
toring of the degree of non-adherence, 
as opposed to purely detecting the drug’s 
presence or not, or utilising the serum 
Z-FHL/HHL ratio (which can be used for all 
ACE inhibitors).
Finally, renal denervation has been 
advocated for the treatment of resistant 
hypertension. The Symplicity 1 and 2 stu-
dies[24,25] showed very promising results. 
However, the definitive Symplicity 3 trial,[26] 
which was a randomised prospective 
blinded study, showed no BP benefit of 
renal denervation over good medical 
management. Unfortunately, definitive 
proof of medication adherence was not 
included as part of the inclusion criteria 
for these trials, possibly resulting in the 
confounding results. In our study, only 
a minority of patients met the inclusion 
criteria for renal denervation, namely office 
systolic BP >160 mmHg and fully adherent. 
In Leicester, the highest percentage 
of lack of adherence to all medications 
was in the group that was referred for 
renal denervation.[23] A recent analysis 
of patients who had stable medication 
adherence showed that renal denervation 
may be useful in cases with poor BP control 
despite documented concentrations of 
antihypertensives.[27]
Study limitations
There are some limitations in our study 
that warrant consideration: (i) we did not 
perform 24-hour BP monitoring to exclude 
pseudo-resistance; (ii) data relating to medi-
cation adherence analysis based on pharmacy 
refills were not available; and (iii) we did 
not assess reasons for lack of adherence. 
Nevertheless, automated clinic BP readings, 
as used in our study, have been shown to 
correlate with 24-hour monitoring and to 
reduce the white-coat effect.[28]
Conclusions
Our results show that patients with thera-
peutic plasma concentrations of amlodipine 
and suppression of ACE have better BP 
control than those who do not. TDM should 
become an essential tool in the evaluation 
of the patient with perceived resistant 
hypertension. This is of particular relevance 
to resource-limited environments, and may 
result in improved BP control, reduction in 
complications, reduced side-effects due to 
polypharmacy and reduction in healthcare 
costs. It will also allow the clinician to focus 
the consultation on the underlying reasons 
for non-adherence. Prospective studies are 
warranted to fully evaluate the potential for 
TDM in hypertensive patients in resource-
limited settings.
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Fig. 1. Blood pressure according to adherence status for amlodipine levels (A) and Z-FHL/HHL (B). 
(DBP = diastolic blood pressure; SPB = systolic blood pressure.)
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